In the second paragraph of the Results the sentence describing the number of studies receiving non-profit or no support should read "The majority of studies adopted a Bayesian framework (n = 214, 67%) and either received non-profit or no support (n = 217, 69%)."

In the final paragraph of the Results the percentage of studies with a closed loop is incorrect. The correct sentence should read "Among studies with a closed loop, i.e., three or more included treatments had been compared in head-to-head trials, 31% did not report the consistency of direct and indirect evidence."

Under Publication Date the p value for 62% versus 79% should read (62% versus 79%, p = 0.0005).

Under Source of Financial Support the p value for 49% versus 28% in the first paragraph should read (49% versus 28%, p = 0.0003).

Under Source of Financial Support the second paragraph should read "Industry-supported studies more often used a Bayesian framework (77% versus 63%, p = 0.0191), and adjusted for study covariates (38% versus 25%, p = 0.0205); however, they less often performed a risk of bias assessment of included studies (54% versus 77%, p∠0.0001), and, for closed loop studies, less often compared the consistency of direct and indirect evidence (39% versus 79%, p∠0.0001)."

In the Discussion the third paragraph should read "An interesting finding is that industry-sponsored studies more often used a Bayesian framework"

[Fig 1](#pone.0131953.g001){ref-type="fig"} is incorrect in the published article. Please see the correct [Fig 1](#pone.0131953.g001){ref-type="fig"} here.

![Identification of network meta-analyses included in review.](pone.0131953.g001){#pone.0131953.g001}

There are errors in [Table 1](#pone.0131953.t001){ref-type="table"} and [Table 2](#pone.0131953.t002){ref-type="table"} of the published article. Please see the correct tables here.

10.1371/journal.pone.0131953.t001

###### Frequency of network meta-analyses (n = 318) by year, indication, and country
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  ------------------------------------------------------------------------------------------------------ -------------
  **Year study published[†](#t001fn001){ref-type="table-fn"}**                                           **n**
  1997                                                                                                   1 (0.3%)
  2003                                                                                                   3 (0.9%)
  2004                                                                                                   1 (0.3%)
  2006                                                                                                   3 (0.9%)
  2007                                                                                                   3 (0.9%)
  2008                                                                                                   9 (2.8%)
  2009                                                                                                   16 (5.0%)
  2010                                                                                                   21 (6.9%)
  2011                                                                                                   44 (13.8%)
  2012                                                                                                   66 (20.4%)
  2013                                                                                                   78 (24.5%)
  2014 (through July 31st)                                                                               73 (23.0%)
  **International Statistical Classification of Diseases (ICD) disease categories**                      **n**
  Blood Disease                                                                                          3 (0.9%)
  Circulatory System                                                                                     64 (20.1%)
  Digestive System                                                                                       13 (4.1%)
  Endocrine, Nutritional, Metabolic, and Immunity                                                        28 (8.8%)
  Genitourinary System                                                                                   7 (2.2%)
  Infectious and Parasite Disease                                                                        14 (4.4%)
  Mental and Behavioral Disorder                                                                         13 (4.1%)
  Musculoskeletal System and Connective Tissue                                                           45 (14.2%)
  Neoplasm                                                                                               39 (12.3%)
  Nervous System and Sensory Organs                                                                      33 (10.4%)
  Respiratory System                                                                                     20 (6.3%)
  Skin and Subcutaneous Tissues                                                                          9 (2.8%)
  Other                                                                                                  30 (9.4%)
  **Country**                                                                                            **n**
  USA                                                                                                    81 (25.5%)
  UK                                                                                                     79 (24.8%)
  Canada                                                                                                 28 (8.8%)
  Italy                                                                                                  21 (6.6%)
  China                                                                                                  16 (5.0%)
  France                                                                                                 14 (4.4%)
  The Netherlands                                                                                        10 (3.1%)
  Germany                                                                                                8 (2.5%)
  Brazil                                                                                                 6 (1.9%)
  Switzerland                                                                                            6 (1.9%)
  Taiwan                                                                                                 6 (1.9%)
  Greece                                                                                                 5 (1.6%)
  Spain                                                                                                  4 (1.3%)
  Other                                                                                                  34 (10.7%)
  **Type of pharmaceutical intervention included**                                                       **n**
  Multiple pharmaceuticals compared                                                                      304 (95.6%)
  Study included a non pharmaceutical treatment (e.g., surgery, exercise, counselling, etc)              30 (9.4%)
  Different strengths of the same pharmaceutical compared (e.g., simvastatin 20mg vs. 40mg)              82 (25.8%)
  Treatments in the same drug class grouped together as a comparator (e.g., beta-blockers, or statins)   75 (23.6%)
  Multiple modes of administration of a drug compared (e.g., oral, sublingual, intramuscular, etc)       10 (3.1%)
  ------------------------------------------------------------------------------------------------------ -------------

† We limited our literature search to studies published in the medical literature. We did not include NMAs submitted to national health technology assessment agencies unless also published in the Ovid-MEDLINE database. \* 'Other countries' includes Greece, Ireland, Singapore, Australia, Cameroon, Denmark, Finland, Hong Kong, Korea, Norway, Poland, and Portugal.
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###### Assessment of network meta-analysis study characteristics
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  Assessment criteria                                                                                                                   All studies (n = 318)   Journal quality (n = 301)[\*](#t002fn002){ref-type="table-fn"}   Date of study publication (n = 318)   Source of study support (n = 315)[\*\*](#t002fn003){ref-type="table-fn"}                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------- ----------------------- ---------------------------------------------------------------- ------------------------------------- -------------------------------------------------------------------------- ---------------- ---------------- ------------ ---------------- ---------------- --------------
  ***General study characteristics***                                                                                                                                                                                                                                                                                                                                                                                              
  Number of treatments compared                                                                                                         6.3 (±6.4)              6.8 (±8.5)                                                       6.0 (±3.9)                            0.3136                                                                     6.0 (±4.2)       6.7 (±8.2)       0.3816       5.9 (±3.6)       6.5 (±7.3)       0.446
  Total number of studies                                                                                                               32.9 (±45.5)            28.3 (±38.6)                                                     36.5 (±46.9)                          0.0992                                                                     30.5 (±50.2)     35.5 (±50.2)     0.3341       22.7 (±29.4)     37.4 (±50.5)     **0.0079**
  Total number of patients                                                                                                              26875 (±65936)          21938 (±46061)                                                   33292 (±82859)                        0.1549                                                                     23711 (±49899)   30460 (±80375)   0.3732       10945 (±13183)   33864 (±77635)   **0.005**
  HTA region (UK, AUS and Canada)[†](#t002fn001){ref-type="table-fn"}                                                                   110 (35%)               50 (34%)                                                         56 (36%)                              0.6709                                                                     68 (41%)         42 (28%)         **0.0156**   48 (49%)         62 (28%)         **0.0003**
  Journal impact factor                                                                                                                 5.5 (±6.2)              NA                                                               NA                                    NA                                                                         5.8 (±6.5)       5.2 (±5.9)       0.3791       3.1 (±1.7)       6.5 (±7.1)       **\<0.0001**
  ***Study method***                                                                                                                                                                                                                                                                                                                                                                                                               
  Bayesian framework                                                                                                                    214 (67%)               91 (62%)                                                         109 (71%)                             0.1038                                                                     106 (63%)        108 (72%)        0.1273       75 (77%)         139 (63%)        **0.0191**
  Risk of bias assessment of included studies                                                                                           223 (70%)               100 (68%)                                                        111 (72%)                             0.4446                                                                     103 (62%)        120 (79%)        **0.0005**   53 (54%)         170 (77%)        **\<0.0001**
  Adjustment for covariates                                                                                                             92 (29%)                35 (24%)                                                         51 (33%)                              0.0744                                                                     54 (32%)         38 (25%)         0.1601       37 (38%)         55 (25%)         **0.0205**
  Random effects model[\*\*\*](#t002fn004){ref-type="table-fn"}                                                                         221 (70%)               98 (67%)                                                         114 (75%)                             0.1609                                                                     116 (69%)        106 (71%)        0.7453       67 (68%)         155 (71%)        0.6243
  Assessment of model fit                                                                                                               127 (40%)               53 (36%)                                                         70 (45%)                              0.0979                                                                     69 (41%)         58 (38%)         0.5985       46 (47%)         81 (37%)         0.0894
  Sensitivity analysis                                                                                                                  179 (56%)               73 (50%)                                                         96 (62%)                              **0.0267**                                                                 88 (53%)         91 (60%)         0.1752       57 (58%)         122 (58%)        0.6542
  Consistency of direct and indirect evidence reported[\*\*\*\*](#t002fn005){ref-type="table-fn"} (closed loop studies only, n = 167)   116 (69%)               39 (57%)                                                         73 (79%)                              **0.0017**                                                                 57 (66%)         59 (73%)         0.3606       16 (39%)         100 (79%)        **\<0.0001**
  ***Study transparency and reproducibility***                                                                                                                                                                                                                                                                                                                                                                                     
  Search terms reported                                                                                                                 254 (80%)               112 (76%)                                                        129 (84%)                             0.1007                                                                     129 (77%)        125 (83%)        0.2201       61 (62%)         193 (88%)        **\<0.0001**
  Network diagram                                                                                                                       194 (61%)               85 (58%)                                                         101 (66%)                             0.1671                                                                     103 (62%)        91 (60%)         0.7974       62 (63%)         132 (60%)        0.5829
  Extracted data from contributing clinical studies                                                                                     206 (65%)               87 (60%)                                                         106 (69%)                             0.0955                                                                     116 (69%)        91 (60%)         0.1011       58 (60%)         149 (68%)        0.1726
  Table of key clinical study characteristics                                                                                           286 (90%)               128 (87%)                                                        141 (92%)                             0.2084                                                                     145 (87%)        141 (93%)        0.0527       89 (91%)         197 (90%)        0.729
  Model code (Bayesian framework only, n = 214)                                                                                         35 (16%)                9 (6%)                                                           24 (16%)                              **0.0085**                                                                 24 (14%)         11 (7%)          **0.0439**   8 (8%)           27 (12%)         0.2811
  ***Presentation of study findings***                                                                                                                                                                                                                                                                                                                                                                                             
  Full matrix of head-to-head comparisons                                                                                               203 (64%)               84 (57%)                                                         108 (70%)                             **0.0191**                                                                 110 (66%)        93 (62%)         0.4294       44 (45%)         159 (73%)        **\<0.0001**
  Reported probability of being best (Bayesian framework only, n = 214)                                                                 87 (41%)                32 (22%)                                                         51 (33%)                              **0.0277**                                                                 41 (25%)         46 (30%)         0.2389       25 (26%)         62 (28%)         0.623
  Ranking of included treatments (Bayesian framework only, n = 214)                                                                     67 (31%)                26 (18%)                                                         40 (26%)                              0.0829                                                                     29 (17%)         39 (26%)         0.0664       11 (11%)         56 (26%)         **0.0031**

† Regions in which submissions to HTA agencies generally require a NMA

\* 17 studies published in journals with no associated impact factor

\*\* 3 studies for which source of study support was unclear

\*\*\* 77 studies reported both fixed and random effects models, 38 studies did not report models used

\*\*\*\* Consistency only reported for studies with a closed loop
